For the treatment of refractory Mycobacterium avium complex (MAC) lung disease, amikacin liposome inhalation suspension (ALIS) (Arikayce, Insmed), first approved by the FDA in 2018, remains effective in these patients after an extended period of therapy, according to updated data from the study that led to the drug’s approval. However, MAC lung disease still poses management challenges for pharmacists and physicians.
The first necessity is to understand just how